Results 121 to 130 of about 13,488 (162)

Association of immune checkpoint inhibitors with muscle mass and density in patients with melanoma. [PDF]

Oncologist
Ziolkowski S, Matheson BE, Boyd SK, Walle M, Gill J, Walker J, Salopek T, Baker JF, Fettahoglu A, Ye C.   +9 more
europepmc   +1 more source

Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. [PDF]

Oncologist
Jamal F, Sahvan O, Junior PLSU, Jones JC, Ou FS, Bekaii-Saab T, Sonbol MB.   +6 more
europepmc   +1 more source

PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. [PDF]

Oncologist
Mohan A, Quingalahua E, Gunchick V, Paul S, Kumar-Sinha C, Crysler O, Zalupski MM, Sahai V.   +7 more
europepmc   +1 more source

First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. [PDF]

Oncologist
Nasca V, Tinè G, Taieb J, Lonardi S, Boursi B, Margalit O, Salvatore L, Cohen R, Ros J, Ambrosini M, Zwart K, Roodhart J, Jayachandran P, Overman MJ, Elez ME, Cremolini C, Tougeron D, Koopman M, André T, Miceli R, Pietrantonio F.   +20 more
europepmc   +1 more source

Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. [PDF]

Oncologist
Moore C, Naraine I, Zhang T.
europepmc   +1 more source

Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines. [PDF]

J Immunother Cancer
Lahusen A, Minhöfer N, Lohse KA, Blechner C, Lindenmayer J, Eiseler T, Wellstein A, Kleger A, Seufferlein T, Windhorst S, Lin YN.   +10 more
europepmc   +1 more source